Compare PRCT & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCT | ADNT |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | 65000 |
| Industry | Medical Specialities | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2021 | 2016 |
| Metric | PRCT | ADNT |
|---|---|---|
| Price | $23.99 | $16.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 12 |
| Target Price | $22.75 | ★ $25.09 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.71 | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | $308,054,000.00 | ★ $17,439,000,000.00 |
| Revenue This Year | $28.44 | N/A |
| Revenue Next Year | $20.02 | $2.58 |
| P/E Ratio | ★ N/A | $41.55 |
| Revenue Growth | ★ 37.22 | 7.56 |
| 52 Week Low | $16.67 | $15.58 |
| 52 Week High | $38.11 | $27.32 |
| Indicator | PRCT | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 37.93 |
| Support Level | $20.22 | N/A |
| Resistance Level | $26.41 | $18.36 |
| Average True Range (ATR) | 1.41 | 0.87 |
| MACD | 0.40 | -0.09 |
| Stochastic Oscillator | 92.41 | 14.94 |
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Adient began trading in October 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market, including unconsolidated joint-venture business. Its share in China is around 20%, down from about 45% following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025, and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. In fiscal 2026 (ended September), consolidated revenue, excluding joint-venture sales, was $15.2 billion.